DOI: 10.5061/dryad.wpzgmsc3g
title: Data from: Early treatment with pyridostigmine alleviates heart failure with preserved ejection fraction (HFpEF) in rats

description: Acetylcholinesterase (AChE) inhibitors constitute a large and chemically
 diverse group of compounds that inhibit the enzyme AChE. Some of these
 compounds that are used to treat Alzheimer’s disease have been reported to
 have favourable cardiovascular effects, i.e., a 35% reduction of the risk
 for cardiovascular disease. There has been a growing interest in AchE
 inhibitors as a potential therapeutic approach for cardiovascular
 diseases, especially heart failure (HF), since they correct the autonomic
 imbalance, a key component in the development of heart failure. In the
 present study, HF was induced in male Wistar albino rats using an
 isoprenaline model (85 mg/kg/day s.c. for 2 days, followed by 3 weeks of
 HF development) of heart failure with preserved ejection fraction (HFpEF).
 Afterwards, rats were treated with pyridostigmine (20 mg/kg/day in tap
 water for 14 days), while the controls received no treatment.
 Electrocardiographic and echosonographic measurements were obtained, and
 samples were taken for antioxidative status measurement and
 histopathological analysis. Administration of pyridostigmine resulted in
 preservation of cardiac contractile function (↑ EF), coupled with a
 decrease in chamber wall thinning (↑ PWDd, ↑ PWDs) and dilatation
 progression (↓ LVIDd, ↓ LVIDs). Additionally, histopathological findings
 showed significantly reduced tissue damage score and attenuation of
 cardiac fibrosis development, indicating the cardioprotective potential of
 pyridostigmine when used as treatment for the early stages of heart
 failure; however, further investigations are needed to fully investigate
 the interplay between the several proposed mechanisms through which AChE
 inhibitors express their protective effects.
description: # Data from: Early treatment with pyridostigmine alleviates heart failure
 with preserved ejection fraction (HFpEF) in rats Dataset DOI:
 [10.5061/dryad.wpzgmsc3g](https://doi.org/10.5061/dryad.wpzgmsc3g) ##
 Description of the data and file structure The data were collected in
 order to investigate the potential cardioprotective effects of a
 peripheral AChE inhibitor, pyridostigmine, administered in the early
 stages of the isoprenaline-induced heart failure in rats.  Male Wistar
 albino rats (n = 24) weighing 310 ± 50 g were used in this experiment.
 Animals were randomized into four groups. Heart failure with preserved
 ejection fraction (HFpEF) was induced in animals in the isoprenaline group
 (I; n = 6) and isoprenaline + pyridostigmine group (I+P; n = 6) by
 administering 85 mg/kg/day of isoprenaline (ISO), s.c., on two consecutive
 days, while animals in the control group (C; n = 6) and the pyridostigmine
 group (P, n = 6) received an equivalent amount of normal saline, s.c.
 Animals were then followed for the next 3 weeks, after which
 echocardiographic (ECHO) measurements were obtained to confirm the
 development of HFpEF in the isoprenaline-treated groups. For the next 14
 days, rats in the P and I+P groups received 20 mg/kg/day of pyridostigmine
 dissolved in drinking water (0.14 mg/mL), while rats in the C and I groups
 remained untreated.  At the end of the experiment, after obtaining
 electrocardiographic (ECG) and ECHO measurements for all groups, the
 animals were anesthetized using a combination of 90 mg/kg ketamine and 10
 mg/kg xylazine and then sacrificed by exsanguination. The tissue and blood
 samples were collected. ### Files and variables #### File:
 Early_treatment_with_pyridostigmine_alleviates_HFpEF_in_rats_raw_data.xlsx
 (or)
 Early_treatment_with_pyridostigmine_alleviates_HFpEF_in_rats_raw_data.csv
 **Description:**  Both XLSX and CSV files are provided. The rows are
 assigned to individual animals, and grouped in experimental groups, while
 the columns contain the measured parameters (i.e., body mass, ECHO...).
 STDEV and average are provided for each group/parameter. Units of
 measurement are listed next to the measured parameters. Blank cells mark
 missing data from animals that have not survived to the end of the
 experiment.  Abbreviations * HW/BW ratio - Heart weight to body weight
 ratio (mg/g) - TBARS- Thiobarbituric Acid Reactive Substances (µmol/L):  *
 NO~2~-: Nitrite (µmol/L) - SOD-Superoxide Dismutase (U/g tissue) *
 GSH: Glutathione  (nmol/g tissue) - CAT: Catalase  (U/g tissue) * IVSd
 (cm) - IVSd—interventricular septum thickness end diastole (cm) *
 IVSs—interventricular septum thickness end systole (cm) - LVIDd—left
 ventricle internal diameter end diastole (cm) * LVIDs—left ventricle
 internal diameter end systole (cm) - PWDd—posterior wall diameter end
 diastole (cm) * PWDs—posterior wall diameter end systole (cm) -
 EDV—end-diastolic volume (mL) * ESV—end-systolic volume (mL) - SV—stroke
 volume (mL) * EF—ejection fraction (%) - HR—heart rate  * bpm - beats per
 minute - PQ/PR—PQ/PR interval (msec) * QT/RT—QT/RT interval (msec) -
 QRS—QRS peak-to-peak voltage amplitude (mV) ## Code/software Microsoft
 Office software. Any program that will open a spreadsheet, such as Excel
 is recommended.